George Badescu, chief business officer at Heidelberg Pharma, discusses antibody-drug conjugate development, partnership styles and the appetite for risk-taking in the biopharma industry.
The cruciality of partnerships in business was stressed by George Badescu, chief business officer (CBO) at oncology therapies company Heidelberg Pharma AG, during a talk at the BIO-Europe Spring conference.
Badescu also profiled the company's lead asset and spoke of a growing appetite for risk-taking in the biopharma industry, while also underlining the increasing value of obtaining and maintaining local...
The whirlwind back-and-forth on US tariffs and Robert F. Kennedy jr.’s plans to deregulate health care have become all-preoccupying, but the National Academy of Medicine was first to set out President Trump’s health administration priorities.
Mikkel Wandahl Pederson, CEO and chief scientific officer at Commit Biologics, discussed the company’s mission to harness the powerful complement system for the treatment of serious diseases.
Phenomix Science presented new data at Digestive Disease Week 2025 showing its machine learning-assisted genetic risk score can predict nausea and side effects from GLP-1 receptor agonists, aiding personalized obesity treatment.
